BR112018004078A2 - composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo - Google Patents

composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo

Info

Publication number
BR112018004078A2
BR112018004078A2 BR112018004078-9A BR112018004078A BR112018004078A2 BR 112018004078 A2 BR112018004078 A2 BR 112018004078A2 BR 112018004078 A BR112018004078 A BR 112018004078A BR 112018004078 A2 BR112018004078 A2 BR 112018004078A2
Authority
BR
Brazil
Prior art keywords
cancer
treating cancer
fusion protein
individual
agent
Prior art date
Application number
BR112018004078-9A
Other languages
English (en)
Inventor
Kwon Hyuk-Sang
Ko Jong-Hee
Lee Yeong-Min
Jung Hyei-Yoon
Yang Seok-Woo
Kang Jae-Hoon
Kim Yong-Sung
Original Assignee
Il Dong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Dong Pharmaceutical Co., Ltd. filed Critical Il Dong Pharmaceutical Co., Ltd.
Publication of BR112018004078A2 publication Critical patent/BR112018004078A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

the present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-vegf) agent are fused, for treating cancer or angiogenesis-related diseases. more specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-vegf agent.
BR112018004078-9A 2015-09-01 2016-09-01 composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo BR112018004078A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0123878 2015-09-01
KR20150123878 2015-09-01
PCT/KR2016/009801 WO2017039358A1 (ko) 2015-09-01 2016-09-01 종양 투과성 펩타이드와 향-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112018004078A2 true BR112018004078A2 (pt) 2018-12-11

Family

ID=58188859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018004078-9A BR112018004078A2 (pt) 2015-09-01 2016-09-01 composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo

Country Status (15)

Country Link
US (1) US10919947B2 (pt)
EP (1) EP3345613B1 (pt)
JP (1) JP6893928B2 (pt)
KR (1) KR102128966B1 (pt)
CN (1) CN108348575B (pt)
AU (1) AU2016317882B2 (pt)
BR (1) BR112018004078A2 (pt)
CA (1) CA2996937C (pt)
DK (1) DK3345613T5 (pt)
ES (1) ES2951260T3 (pt)
FI (1) FI3345613T3 (pt)
MX (1) MX2018002524A (pt)
RU (1) RU2727238C2 (pt)
SI (1) SI3345613T1 (pt)
WO (1) WO2017039358A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
US20200165312A1 (en) * 2017-06-28 2020-05-28 Lg Household & Health Care Ltd. Cosmetic composition for improving skin conditions comprising fusion protein including skin penetration enhancing peptide
AU2018304957A1 (en) * 2017-07-18 2020-02-13 In3Bio Ltd Synthetic proteins and therapeutic uses thereof
CA3075403A1 (en) * 2017-09-08 2019-03-14 Ajou University Industry-Academic Cooperation Foundation Composition for restraining activity of regulatory t cell, comprising peptide binding specifically to neuropilin 1 (nrp1)
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CN113164544A (zh) * 2018-10-12 2021-07-23 三钰生物科技股份有限公司 双功能性融合蛋白及其用途
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
CN112522322A (zh) * 2020-12-24 2021-03-19 深圳市人民医院 一种nrp1配体的修饰技术
CN114028541A (zh) * 2021-05-21 2022-02-11 中山大学 Gdf2在制备改善肿瘤异常血管的药物中的用途
WO2023134787A2 (zh) * 2022-01-14 2023-07-20 上海君实生物医药科技股份有限公司 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
KR102459219B1 (ko) * 2022-03-31 2022-10-26 주식회사 셀아이콘랩 신규한 피부투과성 펩타이드, 이를 포함하는 피부 및 점막 조성물과 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06006406A (es) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
RU2008106230A (ru) * 2005-07-19 2009-08-27 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования
MX2009012968A (es) 2007-06-06 2010-04-01 Domantis Ltd Polipeptidos, dominios variables de anticuerpo y antagonistas.
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2766634A1 (en) * 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
EP4306123A3 (en) * 2011-12-22 2024-04-17 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9116159B2 (en) * 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
WO2014189303A1 (ko) * 2013-05-23 2014-11-27 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도

Also Published As

Publication number Publication date
EP3345613A1 (en) 2018-07-11
EP3345613A4 (en) 2019-08-14
US20180237484A1 (en) 2018-08-23
KR20170027312A (ko) 2017-03-09
CN108348575A (zh) 2018-07-31
RU2018111390A3 (pt) 2020-01-31
CA2996937C (en) 2024-02-06
ES2951260T3 (es) 2023-10-19
CA2996937A1 (en) 2017-03-09
CN108348575B (zh) 2022-06-14
AU2016317882B2 (en) 2021-01-28
RU2727238C2 (ru) 2020-07-21
EP3345613B1 (en) 2023-05-10
US10919947B2 (en) 2021-02-16
JP6893928B2 (ja) 2021-06-23
JP2018531989A (ja) 2018-11-01
FI3345613T3 (fi) 2023-07-28
RU2018111390A (ru) 2019-10-04
SI3345613T1 (sl) 2023-10-30
DK3345613T5 (da) 2024-09-30
AU2016317882A1 (en) 2018-04-19
DK3345613T3 (da) 2023-07-31
WO2017039358A1 (ko) 2017-03-09
MX2018002524A (es) 2018-11-09
KR102128966B1 (ko) 2020-07-01

Similar Documents

Publication Publication Date Title
BR112018004078A2 (pt) composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA201792047A1 (ru) Новые соединения
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
EA201491644A1 (ru) Фармацевтические композиции
PE20181159A1 (es) Proteinas de fusion para tratar trastornos metabolicos
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
EA201690159A1 (ru) Способы и композиции для лечения рака
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]